"Galactosylceramides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cerebrosides which contain as their polar head group a galactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in beta-galactosidase, is the cause of galactosylceramide lipidosis or globoid cell leukodystrophy.
| Descriptor ID |
D005699
|
| MeSH Number(s) |
D02.065.313.250.450 D09.400.410.420.525.200.250.450 D10.390.470.675.200.250.450 D10.570.877.360.612.200.250.450
|
| Concept/Terms |
Galactosylceramides- Galactosylceramides
- Galactosyl Ceramides
- Ceramides, Galactosyl
- Galactocerebrosides
|
Below are MeSH descriptors whose meaning is more general than "Galactosylceramides".
Below are MeSH descriptors whose meaning is more specific than "Galactosylceramides".
This graph shows the total number of publications written about "Galactosylceramides" by people in this website by year, and whether "Galactosylceramides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Galactosylceramides" by people in Profiles.
-
Reduced dose of PTCy followed by adjuvant a-galactosylceramide enhances GVL effect without sacrificing GVHD suppression. Sci Rep. 2021 06 23; 11(1):13125.
-
Donor Treg expansion by liposomal a-galactosylceramide modulates Tfh cells and prevents sclerodermatous chronic graft-versus-host disease. Immun Inflamm Dis. 2021 09; 9(3):721-733.
-
IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol. 2018 10 01; 201(7):2141-2153.
-
Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge. PLoS One. 2014; 9(3):e90001.
-
C-Glycosphingolipids with an exo-methylene substituent: stereocontrolled synthesis and immunostimulation of mouse and human natural killer T lymphocytes. Chembiochem. 2012 Aug 13; 13(12):1733-7.
-
Intranasal but not intravenous delivery of the adjuvant a-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. Eur J Immunol. 2011 Nov; 41(11):3312-22.
-
Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine. 2009 May 26; 27(25-26):3484-8.
-
Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine. 2009 May 26; 27(25-26):3335-41.
-
Synthesis and evaluation of an alpha-C-galactosylceramide analogue that induces Th1-biased responses in human natural killer T cells. Chembiochem. 2006 Nov; 7(11):1750-6.
-
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia. 2003 Jun; 17(6):1068-77.